Hematologic cancer is a disease that affects the blood, bone marrow and lymphoid organs. It is the fifth most frequent cancer and the second cause of death due to malignant tumors; it occurs in 93 people out of 100 thousand. The most common are leukemias, lymphomas, and myeloma. This condition accounts for between 8 and 10 percent of all malignant tumors. Advances and innovations in immunotherapy are a great hope to combat them.
In the field of immunotherapy, as in other areas of precision medicine, hematology has been a pioneer and has obtained significant improvements in the survival and quality of life of patients, so that now they only have to worry about minor problems like a pedicure or dental crowns in Tijuana Mexico if you need to improve your smile.
He also pointed out that in the specific case of therapy with T-CAR cells synthetic immuno-receptors that can redirect T lymphocytes to recognize and destroy tumor cells selectively, the collaboration between hematologists and immunologists has been key to their development.
It constitutes a revolution in the treatment of various malignant hematological diseases, with great perspectives for patients who were previously incurable.
For his part, the head of the section in the Hematology Service expressed that for the moment, this therapy has been effective in acute lymphoblastic leukemia of B cells, aggressive non-Hodgkin B lymphoma and chronic lymphocytic leukemia. Similarly, he reported that he is testing multiple myeloma with perfect expectations.
Finally, the specialties addressed the challenges of the present and future of this area, among which they stated that they are: T-CAR cell therapy since its long-term efficacy must be confirmed, immediate complications reduced, and administered in phases Earlier diseases, explore new indications, simplify their production and make costs affordable.
Also, monoclonal antibodies because it is necessary to search for combinations to achieve higher levels of efficacy and control toxicity, and the development of personalized therapeutic vaccines against cancer for each type of patient, since they are other of the enormous challenges of immunotherapy.